ELDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Eledon Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.16+0.03 (+1.41%)
Close on Oct 19, 2026
- Market cap
- $245.44M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
57.8%
47M of 81M shares
Institutional holders
161
51 new, 9 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lampert Mark N | 7,868,419 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Matthew D. Perry | 4,762,691 | 5.98% | 13G (passive) | Nov 19, 2025 |
| BlackRock, Inc. | 4,380,857 | 5.80% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 3,898,446 | 5.05% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ELDN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bvf Inc/Il | 6,293,282 | 7.74% | $24.80M | – | 0.63% |
| BlackRock, Inc. | 5,123,842 | 6.31% | $20.19M | +741,597 | 0.00% |
| Defilade Capital Management, L.P. | 3,525,338 | 4.34% | $13.89M | −38,789 | 1.86% |
| Vanguard Capital Management LLC | 3,417,223 | 4.21% | $13.46M | +124,089 | 0.00% |
| Goldman Sachs Group Inc | 2,510,308 | 3.09% | $9.89M | +2,140,218 | 0.00% |
| Ensign Peak Advisors, Inc | 2,101,224 | 2.59% | $8.28M | −363,695 | 0.01% |
| Geode Capital Management, LLC | 1,956,601 | 2.41% | $7.71M | +164,818 | 0.00% |
| Catalio Capital Management, LP | 1,695,071 | 2.09% | $6.68M | +55,255 | 1.26% |
| State Street Corp | 1,621,969 | 2.00% | $6.39M | +467,298 | 0.00% |
| Zimmer Partners, LP | 1,596,599 | 1.96% | $6.29M | −278,401 | 0.14% |
| Sphera Funds Management Ltd. | 1,191,187 | 1.47% | $4.69M | −580,944 | 0.61% |
| AWM Investment Company, Inc. | 1,100,000 | 1.35% | $4.33M | – | 0.38% |
| UBS Group AG | 1,048,245 | 1.29% | $4.13M | +500,798 | 0.00% |
| Kingdon Capital Management, L.L.C. | 1,039,275 | 1.28% | $4.09M | – | 0.42% |
| Millennium Management LLC | 979,712 | 1.21% | $3.86M | New | 0.00% |
| Bank Of America Corp /De/ | 883,097 | 1.09% | $3.48M | +13,553 | 0.00% |
| ADAR1 Capital Management, LLC | 647,812 | 0.80% | $2.55M | −326,609 | 0.12% |
| 22NW, LP | 636,364 | 0.78% | $2.51M | – | 2.40% |
| Northern Trust Corp | 616,399 | 0.76% | $2.43M | +72,557 | 0.00% |
| Aqr Capital Management LLC | 581,028 | 0.72% | $2.29M | +408,611 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 161 | 47M | 57.8% | 51 / 62 | 22 / 9 | 10M | 5M |
| Q1 2026 | 121 | 43M | 52.4% | 42 / 35 | 20 / 15 | 8M | 6M |
| Q4 2025 | 95 | 44M | 54.3% | 32 / 32 | 17 / 19 | 18M | 11M |
| Q3 2025 | 83 | 36M | 44.9% | 21 / 23 | 22 / 21 | 7M | 11M |
| Q2 2025 | 85 | 41M | 50.3% | 28 / 21 | 15 / 26 | 6M | 4M |
| Q1 2025 | 83 | 38M | 47.3% | 18 / 17 | 21 / 10 | 4M | 5M |
| Q4 2024 | 75 | 38M | 47.4% | 45 / 19 | 2 / 3 | 23M | 3M |
| Q3 2024 | 33 | 18M | 22.7% | 3 / 9 | 7 / 1 | 1M | 1M |
| Q2 2024 | 32 | 19M | 23.2% | 7 / 14 | 2 / 4 | 9M | 0M |
| Q1 2024 | 29 | 10M | 11.8% | 3 / 9 | 8 / 3 | 1M | 0M |
| Q4 2023 | 29 | 9M | 11.3% | 5 / 8 | 7 / 3 | 1M | 0M |
| Q3 2023 | 28 | 9M | 11.0% | 3 / 8 | 9 / 8 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ELDN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,483,162 | 3.06% | $9.78M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,038,160 | 2.51% | $8.03M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 854,634 | 1.05% | $3.37M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 839,205 | 1.03% | $2.84M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 723,407 | 0.89% | $2.85M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 389,371 | 0.48% | $1.48M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 383,983 | 0.47% | $1.46M | 0.01% | May 31, 2026 |
| Goldman Sachs Small Cap Equity Insights Fund | 311,993 | 0.38% | $1.05M | 0.10% | Jul 31, 2026 |
| Goldman Sachs Small Cap Value Insights Fund | 286,012 | 0.35% | $966.72K | 0.07% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 255,233 | 0.31% | $1.01M | 0.07% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 196,897 | 0.24% | $665.51K | 0.00% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 187,417 | 0.23% | $633.47K | 0.01% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 141,649 | 0.17% | $539.68K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 134,953 | 0.17% | $531.71K | 0.01% | Jun 30, 2026 |
| Goldman Sachs Small Cap Growth Insights Fund | 129,548 | 0.16% | $437.87K | 0.13% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven Perrin | President, Director | 153,353 | 0.19% | Aug 4, 2026 |
| David-Alexandre C. Gros | Chief Executive Officer, Director | 363,454 | 0.45% | Aug 4, 2026 |
| Bryan E. Smith | General Counsel, Corporate Sec | – | – | Jan 13, 2025 |
| Paul Sean Little | Chief Financial Officer | 10,000 | 0.01% | Jan 13, 2025 |
| James A. Robinson Jr. | Director | 3,430 | 0.00% | Jan 16, 2026 |
| John S. McBride | Director | 3,430 | 0.00% | Jan 16, 2026 |
| Keith Katkin | Director | 8,575 | 0.01% | Jan 16, 2026 |
| June Lee | Director | 3,430 | 0.00% | Jan 16, 2026 |
| Jan Hillson | Director | 3,430 | 0.00% | Jan 16, 2026 |
| Allan Kirk | Director | 3,430 | 0.00% | Jan 16, 2026 |
| Ii Gp Llc Bvf | – | – | – | Oct 31, 2024 |
| Value Fund Ii Lp Biotechnology | – | 3,361,803 | 4.14% | Oct 31, 2024 |
| I. Gp Llc Bvf | – | – | – | Oct 31, 2024 |
| Gp Holdings Llc Bvf | 10% owner | 77,936 | 0.10% | Oct 31, 2024 |
| Inc/Il Bvf | 10% owner | 220,460 | 0.27% | Oct 31, 2024 |
| Mark N. Lampert | 10% owner | 58,688 | 0.07% | Oct 31, 2024 |
| Value Trading Fund OS LP Biotechnology | – | 2,330,418 | 2.87% | Oct 31, 2024 |
| Partners L. P/Il Bvf | 10% owner | – | – | Oct 31, 2024 |
| Value Fund L. P. Biotechnology | – | – | – | Oct 31, 2024 |
| Partners OS Ltd. BVF | – | – | – | Oct 31, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David-Alexandre C. Gros Chief Executive Officer, Director | Jul 31, 2026 | Award | +354,454 | – | – | 363,454 |
| David-Alexandre C. Gros Chief Executive Officer, Director | Jul 31, 2026 | Tax withholding | −194,791 | $3.38 | $658.39K | 168,663 |
| Steven Perrin President, Director | Jul 31, 2026 | Award | +152,353 | – | – | 153,353 |
| Steven Perrin President, Director | Jul 31, 2026 | Tax withholding | −72,138 | $3.38 | $243.83K | 81,215 |
| John S. McBride Director | Jan 10, 2026 | Option exercise | +3,430 | – | – | 3,430 |
| Jan Hillson Director | Jan 10, 2026 | Option exercise | +3,430 | – | – | 3,430 |
| James A. Robinson Jr. Director | Jan 10, 2026 | Option exercise | +3,430 | – | – | 3,430 |
| June Lee Director | Jan 10, 2026 | Option exercise | +3,430 | – | – | 3,430 |
| Allan Kirk Director | Jan 10, 2026 | Option exercise | +3,430 | – | – | 3,430 |
| Keith Katkin Director | Jan 10, 2026 | Option exercise | +8,575 | – | – | 8,575 |
| Inc/Il Bvf 10% owner | May 9, 2024 | Buy | +75,431 | – | – | 220,460 |
| Inc/Il Bvf 10% owner | May 9, 2024 | Buy | +821,121 | – | – | 2,633,679 |
| Inc/Il Bvf 10% owner | May 9, 2024 | Buy | +1,031,385 | – | – | 3,361,803 |
| Value Trading Fund OS LP Biotechnology – | May 5, 2023 | Buy | +1,055,445 | – | – | 2,330,418 |
| Value Trading Fund OS LP Biotechnology – | May 5, 2023 | Buy | +86,341 | – | – | 145,029 |
| Value Trading Fund OS LP Biotechnology – | May 5, 2023 | Buy | +837,146 | – | – | 1,812,558 |
| Steven Perrin President, Director | Nov 23, 2022 | Buy | +1,000 | $2.60 | $2.60K | 1,000 |
| David-Alexandre C. Gros Chief Executive Officer, Director | Dec 20, 2021 | Buy | +2,000 | $4.48 | $8.96K | 9,000 |
| David-Alexandre C. Gros Chief Executive Officer, Director | Aug 17, 2021 | Buy | +4,000 | $6.21 | $24.84K | 7,000 |
| Paul Sean Little CHIEF FINANCIAL OFFICER | Jun 11, 2021 | Buy | +10,000 | $8.87 | $88.70K | 10,000 |
| David-Alexandre C. Gros Chief Executive Officer, Director | Jun 9, 2021 | Buy | +3,000 | $8.01 | $24.03K | 3,000 |
| Mark N. Lampert – | Dec 22, 2020 | Conversion | +11,278 | – | – | 89,214 |
| Mark N. Lampert – | Dec 22, 2020 | Conversion | +15,166 | – | – | 117,565 |
| Mark N. Lampert – | Dec 22, 2020 | Conversion | +654,215 | – | – | 771,780 |
| Mark N. Lampert – | Dec 22, 2020 | Conversion | +509,410 | – | – | 598,624 |
| Mark N. Lampert – | Dec 22, 2020 | Conversion | +97,615 | – | – | 113,152 |
| Mark N. Lampert – | Dec 22, 2020 | Conversion | +1,944 | – | – | 15,537 |
| Israel GP Ltd. OrbiMed 10% owner | Dec 2, 2020 | Sale | −103,200 | $21.60 | $2.23M | 73,650 |
| Global Management LP Logos 10% owner | Oct 30, 2020 | Sale | −12,942 | $26.64 | $344.77K | 187,058 |
| Global Management LP Logos 10% owner | Oct 30, 2020 | Buy | +15,000 | $26.17 | $392.55K | 214,973 |
| Global Management LP Logos 10% owner | Oct 30, 2020 | Sale | −27 | $27.02 | $730 | 199,973 |
| Global Management LP Logos 10% owner | Oct 30, 2020 | Buy | +12,942 | $25.88 | $334.94K | 200,000 |
| Global Management LP Logos 10% owner | Oct 30, 2020 | Buy | +9,098 | $25.55 | $232.45K | 224,071 |
| Global Management LP Logos 10% owner | Oct 30, 2020 | Buy | +15,000 | $26.48 | $397.20K | 200,000 |
| Global Management LP Logos 10% owner | Oct 30, 2020 | Buy | +4,000 | $25.97 | $103.88K | 185,000 |
| Global Management LP Logos 10% owner | Oct 30, 2020 | Buy | +31,000 | $24.53 | $760.43K | 181,000 |
| Global Management LP Logos 10% owner | Oct 30, 2020 | Buy | +5,000 | $24.03 | $120.15K | 150,000 |
| Jon Kuwahara See Remarks | May 21, 2019 | Sale | −1,058 | $1.91 | $2.02K | 5,974 |
| Gregory J. Flesher Chief Executive Officer, Director | May 21, 2019 | Sale | −2,937 | $1.91 | $5.61K | 156,918 |
| Catherine C. Turkel President | May 21, 2019 | Sale | −1,914 | $1.91 | $3.66K | 88,662 |
| Jon Kuwahara See Remarks | May 20, 2019 | Sale | −4,218 | $1.96 | $8.27K | 7,032 |
| Gregory J. Flesher Chief Executive Officer, Director | May 20, 2019 | Sale | −11,701 | $1.96 | $22.93K | 159,855 |
| Catherine C. Turkel President | May 20, 2019 | Sale | −7,623 | $1.96 | $14.94K | 90,576 |
| Israel BioFund GP Limited Partnership OrbiMed Director, 10% owner | May 2, 2019 | Buy | +646,204 | $3.10 | $2.00M | 3,183,314 |
| Erez Chimovits Director | May 2, 2019 | Buy | +646,204 | $3.10 | $2.00M | 3,183,314 |
| Paul Yook 10% owner | Apr 30, 2019 | Sale | −200 | $2.70 | $540 | 1,065,867 |
| Catherine C. Turkel President | Mar 14, 2019 | Award | +20,000 | – | – | 98,199 |
| Gregory J. Flesher Chief Executive Officer, Director | Mar 14, 2019 | Award | +25,000 | – | – | 171,556 |
| Catherine C. Turkel President | Sep 12, 2018 | Buy | +16,632 | $5.02 | $83.49K | 78,199 |
| Catherine C. Turkel President | Sep 11, 2018 | Buy | +17,048 | $4.56 | $77.74K | 61,567 |
| Catherine C. Turkel President | Sep 5, 2018 | Buy | +805 | $3.97 | $3.20K | 805 |
| Jon Kuwahara See Remarks | Mar 13, 2018 | Award | +11,250 | – | – | 11,250 |
| Catherine C. Turkel President | Mar 13, 2018 | Award | +20,000 | – | – | 44,519 |
| Gregory J. Flesher Chief Executive Officer, Director | Mar 13, 2018 | Award | +30,700 | – | – | 146,556 |
| Gregory J. Flesher Chief Executive Officer, Director | May 10, 2017 | Buy | +58,959 | $9.99 | $589.00K | 115,856 |
| Catherine C. Turkel Chief Development Officer | May 10, 2017 | Buy | +11,111 | $9.99 | $111.00K | 24,519 |
| Christine Ocampo See Remarks | May 10, 2017 | Buy | +10,010 | $9.99 | $100.00K | 21,590 |
| Israel BioFund GP Limited Partnership OrbiMed Director, 10% owner | May 9, 2017 | Award | +2,537,110 | – | – | 2,537,110 |
| Stephen Buckley Jr. Director | Mar 15, 2016 | Buy | +8,000 | $5.74 | $45.92K | 11,000 |
| Jodie Pope Morrison President and CEO, Director | Jan 8, 2016 | Option exercise | +20,000 | $1.37 | $27.40K | 57,566 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.